Welcome to our dedicated page for Ani Pharmaceutic SEC filings (Ticker: ANIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ANI Pharmaceuticals, Inc. filings document financial results, operating updates, governance matters, and material events for its Rare Disease, Generics, and Brands businesses. Form 8-K reports furnish earnings releases, preliminary results, guidance updates, Regulation FD investor presentations, and corporate changes such as independent auditor matters.
ANI proxy filings cover shareholder voting items, board governance, executive compensation, equity awards, and related governance disclosures. The filing record also provides formal context for product and business risks tied to biopharmaceutical development, FDA-regulated generic launches, branded products, commercialization, manufacturing, and capital actions.
ANIP submitted a Form 144 notice reporting a proposed sale of 6,000 common shares through Morgan Stanley Smith Barney LLC. The filing lists restricted stock lots dated 04/27/2023 (1,698 shares), 05/23/2024 (3,865 shares) and 05/21/2025 (437 shares).
ANI Pharmaceuticals is highlighting strong recent growth and ambitious 2026 goals as it meets institutional investors and updates its investor presentation. Total net revenue reached $883 million in 2025, a 44% year-over-year increase, driven by both rare disease and generics.
Lead rare disease drug Cortrophin Gel generated $348 million in 2025 revenue, up 76%, while ILUVIEN contributed $75 million. Adjusted non-GAAP EBITDA was $230 million, up 47%, and adjusted non-GAAP diluted EPS was $7.89, a 52% increase.
For 2026, the company is guiding to $1.055–$1.115 billion in total net revenue and $275–$290 million in adjusted non-GAAP EBITDA, implying roughly low‑20% growth at the midpoint. Rare disease products are expected to provide about 60% of 2026 revenue, with Cortrophin Gel forecast at $540–$575 million and ILUVIEN at $78–$83 million. Adjusted non-GAAP diluted EPS is projected at $8.83–$9.34 and adjusted gross margin at 59.3%–60.3%.
The strategy centers on accelerating transformation into a leading rare disease company, including a new ~90-person commercial organization for acute gouty arthritis flares and continued investment in Phase 4 trials and real‑world evidence for Cortrophin Gel. The generics segment, with about $384 million in 2025 revenue, remains an important cash generator supported by three U.S. manufacturing sites and a pipeline targeting 10–15 launches annually. Year-end 2025 cash was $286 million with net leverage of about 1.5x, supporting ongoing investment and disciplined capital allocation.
Shanmugam Muthusamy reported acquisition or exercise transactions in this Form 4 filing.
ANI Pharmaceuticals director and executive Shanmugam Muthusamy received a grant of 11,116 shares of common stock as a restricted stock award. The award was granted on February 26, 2026 at $77.15 per share and will vest in four equal annual installments on the first, second, third and fourth anniversaries of that date.
After this grant, he directly holds 101,056 common shares. He also has indirect ownership over 431,920 shares held by Esjay LLC and 5,000 shares held by SS Pharma LLC, where he holds voting and dispositive power over the shares.
ANI Pharmaceuticals executive Thomas Andrew Rowland, SVP and Head of Established Brands, reported equity compensation activity in company common stock. On February 26, 2026, he acquired 6,021 shares as a restricted stock award at $77.15 per share. This award will vest in four equal annual installments on the first through fourth anniversaries of February 26, 2026.
On February 28, 2026, 628 shares were disposed of at $73.90 per share to cover tax withholding in connection with the vesting of 2,171 previously granted restricted shares. After these transactions, he directly holds 43,502 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals executive Christopher Mutz reported two equity-related transactions in company stock. On February 26, 2026, he acquired 21,306 shares of common stock through a restricted stock award that will vest in four equal annual installments on each anniversary of February 26, 2026.
On February 28, 2026, 2,221 shares of common stock were disposed of to cover tax withholding in connection with the vesting of 4,342 previously granted restricted shares, a transaction exempt under Rule 16(b)-3. After these transactions, Mutz directly owned 103,925 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals President and CEO Nikhil Lalwani reported two equity compensation events involving the company’s common stock. On February 26, 2026, he acquired 75,592 shares through a restricted stock award at $77.15 per share. According to the footnotes, this award will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026, tying his compensation to multi‑year performance.
On February 28, 2026, Lalwani had 12,217 shares withheld at $73.90 per share as a tax-withholding disposition in connection with the vesting of 23,883 previously granted restricted shares. These shares were withheld for tax purposes and are exempt under Rule 16(b)-3, rather than being an open-market sale. After these transactions, his directly owned common stock holdings were reported at 434,166 shares following the award and 421,949 shares following the tax withholding.
ANI Pharmaceuticals senior vice president of generics, Ori Gutwerg, reported two equity-related transactions in common stock. On February 26, 2026, he acquired 12,969 shares at $77.15 per share as a grant or award, bringing his direct holdings to 89,063 shares. According to a footnote, this restricted stock award will vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026.
On February 28, 2026, 2,221 shares were disposed of at $73.90 per share in a tax-withholding disposition related to the vesting of 4,342 previously granted restricted shares, leaving Gutwerg with 86,842 directly owned shares.
ANI Pharmaceuticals SVP Chad Gassert reported equity compensation and related tax withholding transactions in company stock. On February 26, 2026, he acquired 11,116 shares of common stock as a restricted stock award at $77.15 per share, scheduled to vest in four equal annual installments on the first through fourth anniversaries of February 26, 2026.
On February 28, 2026, 2,221 shares were withheld at $73.90 per share to cover taxes tied to the vesting of 4,342 previously granted restricted shares, leaving 74,916 shares held directly. He also has indirect ownership of 158,490 shares held by Chali Properties LLC, over which he holds voting and dispositive power.
ANI Pharmaceuticals senior vice president and chief HR officer Krista Davis reported two stock transactions involving company common shares. On February 26, 2026, she acquired 10,810 shares through a restricted stock award at $77.15 per share, bringing her direct holdings to 60,073 shares. This award is scheduled to vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026. On February 28, 2026, 1,555 shares were withheld at $73.90 per share to cover tax obligations related to the vesting of a prior restricted stock grant, leaving her with 58,518 directly owned shares. The tax withholding is characterized as a payment of tax liability by delivering securities, not an open-market sale.
ANI Pharmaceuticals senior vice president and general counsel Meredith Cook reported equity compensation activity in company stock. On February 26, 2026, Cook acquired 13,895 shares of common stock as a restricted stock award at $77.15 per share, which will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026. On February 28, 2026, 1,555 shares at $73.90 per share were disposed of through shares withheld for tax purposes in connection with the vesting of 3,040 previously granted restricted shares. After these transactions, Cook directly owned 79,890 shares of ANI Pharmaceuticals common stock.